Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,539 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT07062536RecruitingPhase 2
Comparing Two Chemo Combos for Advanced Bile Duct Cancer
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Busan, BusanAges 19–99 - NCT07049133Recruiting
Tracking side effects of T-DXd for advanced breast cancer
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
MilanAges 18 years+ - NCT07035002RecruitingPhase 1
PD-1 knockout TILs for advanced colorectal cancer
This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.
Shanghai, None SelectedAges 18–70 - NCT07040228RecruitingPhase 1/Phase 2
Study of regorafenib, toripalimab, and chemo for advanced pancreatic cancer
This trial tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for advanced pancreatic cancer that has progressed after two prior therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shenzhen, GuangdongAges 18–80 - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07016724RecruitingPhase 2
Study of radiation and chemo with cadonilizumab for esophageal cancer
This trial tests combining radiation, chemotherapy, and the drug cadonilizumab before surgery for locally advanced esophageal squamous cell cancer. It aims to shrink the tumor and improve treatment outcomes.
Zhengzhou, HenanAges 18–75 - NCT07008976RecruitingPhase 3
Testing TQB2102 versus standard treatment for HER2-positive advanced breast cancer
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Bengbu, AnhuiAges 18–75 - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT06962787RecruitingPhase 2
Study of BL-B01D1 + TKI with or without pembrolizumab for advanced kidney cancer
This trial is testing a new drug combination for people with advanced kidney cancer. The main drug, BL-B01D1, is given together with a targeted therapy (TKI) and sometimes also with an immunotherapy drug (pembrolizumab). The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT05874063RecruitingPhase 3
Preventing blood clots during first chemotherapy for germ cell tumors
This Phase 3 study tests whether giving enoxaparin (a blood thinner) can prevent dangerous blood clots in people with advanced germ cell tumors starting their first chemotherapy. It is especially focused on people who are at higher risk of clots.
AngersAges 18 years+ - NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06921837RecruitingPhase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
Darlinghurst, New South WalesAges 18 years+ - NCT06903858RecruitingPhase 2
Toripalimab plus celecoxib for dMMR/MSI-H colorectal cancer
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06897644RecruitingPhase 3
Comparing two chemotherapy strategies for advanced pancreatic cancer
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
AvianoAges 18 years+ - NCT06885697RecruitingPhase 1
CAR T-cell therapy for mesothelioma and other solid tumors
This study tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack cancer cells with a protein called mesothelin on their surface. It may help people with mesothelioma or other solid tumors that have not improved with standard treatments.
Bethesda, MarylandAges 18–120 - NCT06866964RecruitingPhase 2
Aspirin to prevent blood clots in advanced germ cell cancer chemotherapy
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
Charlotte, North CarolinaAges 18–70 - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT06825715Recruiting
Precision oncology support for lung and prostate cancer
This study tests a program to help veterans with lung or prostate cancer get personalized cancer treatments. The goal is to see if extra support for doctors and patients leads to better use of precision medicine.
New York, New YorkAges Any age - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,539 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.